Rutaecarpine Attenuates Monosodium Urate Crystal-Induced Gouty Inflammation via Inhibition of TNFR-MAPK/NF-κB and

Min Li1, Zhu-Jun Yin2,3, Li Li2

  • 1Department of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.

Abstract

Insights

Rutaecarpine (RUT) effectively reduced inflammation in a gout model by inhibiting key inflammatory pathways. This suggests RUT shows promise as a potential therapeutic agent for gout treatment.

Area of Science:

  • Pharmacology
  • Immunology
  • Inflammation Research

Background:

  • Gout is a painful inflammatory condition caused by monosodium urate (MSU) crystals.
  • Current treatments may have side effects, necessitating the search for novel therapeutic agents.

Purpose of the Study:

  • To evaluate the anti-inflammatory effects of rutaecarpine (RUT) in an MSU-induced murine peritonitis model.
  • To elucidate the underlying molecular mechanisms of RUT in lipopolysaccharide (LPS)/MSU-induced gout in vitro.

Main Methods:

  • MSU-induced peritonitis model in mice and LPS/MSU-treated THP-1 macrophages.
  • Assays included ELISA, flow cytometry, qRT-PCR, Western blot, SPR, and molecular docking.
  • Evaluated cytokine levels, neutrophil infiltration, pyroptosis, and key signaling pathway proteins.

Main Results:

  • RUT significantly reduced neutrophil and monocyte infiltration and decreased pro-inflammatory cytokines (IL-1β, IL-6, TNF-α).
  • RUT inhibited mRNA and protein expression of key inflammatory mediators and signaling molecules (TNFR1, MAPK, NF-κB, NLRP3 inflammasome components).
  • Surface plasmon resonance and molecular docking confirmed RUT's direct binding to TNF-α.

Conclusions:

  • RUT demonstrates significant anti-inflammatory effects in gout models.
  • RUT acts by inhibiting the TNFR1-MAPK/NF-κB and NLRP3 inflammasome pathways.
  • RUT is a potential therapeutic candidate for managing gouty inflammation.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.4K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.2K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
4.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316